beep beep beep WHAT IS TODA'YS DATE?
--> Piper radar 'locked' on CymaBay EASL poster presentations on June 23 12:03 CBAY
WHO'S FEELING LUCKY!!!! EVERYTHING I AM DOING TODAY IS WORKING MAYBE I SHOULDN'T STOP!!!
JonesTrading starts CymaBay with Buy, $8 target on seladelpar potential 06/14 CBAY JonesTrading analyst Prakhar Agrawal initiated coverage of CymaBay Therapeutics with a Buy rating and $8 price target. CymaBay is a clinical-stage biopharma focused on the development of drugs for liver and other chronic diseases, Agrawal tells investors in a research note. The analyst says the company's seladelpar will not only have a "meaningfully better profile" in primary biliary cholangitis compared to the only approved branded drug Ocaliva, but it will also set a "very high bar making it very tough for future competitors to differentiate." Agrawal believes is seladelpar is "de-risked" in PBC and that its potential is not priced into the shares. Show Related Items >>
